AXSMのチャート
AXSMの企業情報
| symbol | AXSM |
|---|---|
| 会社名 | Axsome Therapeutics Inc （アクサム・セラピュ―ティクス） |
| 分野（sector） | Health Care ヘルスケア |
| 産業（industry） | Major Pharmaceuticals |
| 業種 | バイオテクノロジ―_メディカルリサ―チ 医療関連（Health Care） |
| 概要 | 事業概要 Axsome Therapeutics Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies for the management of central nervous system (CNS) disorders including pain. It operates in the business of developing novel therapies for the management of CNS disorders segment. Its product candidate AXS-02 (disodium zoledronate tetrahydrate) is an oral targeted non opioid therapeutic for chronic pain. It is developing AXS 02 for the treatment of pain in over three conditions such as complex regional pain syndrome (CRPS); knee osteoarthritis (OA) associated with bone marrow lesions (BMLs) and chronic low back pain (CLBP) associated with type I or mixed type I and type II Modic changes (MCs). Its product candidate AXS 05 is a fixed dose combination of dextromethorphan (DM) and bupropion. It is developing AXS 05 for the treatment of over two conditions such as treatment resistant depression (TRD) and agitation in patients with Alzheimer''s disease (AD). アクサム・セラピュ―ティクスは米国のバイオ医薬品企業。臨床段階で、痛みと中枢神経系障害のための治療法の開発に従事。医薬品候補の「AXS-02」は非オピオイドの経口薬で、慢性的な痛みの治療に使用される。また「AXS-05」はデキストロメトルファンとブプロピオンの一定量を組み合わせた革新的な治療薬である。本社はニューヨーク。 Axsome Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its product candidates include AXS-05, AXS-07, AXS-09, AXS-12, and AXS-14 which are developing for multiple pain and primary care indications. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY. |
| 本社所在地 | 25 Broadway 9th Floor New York NY 10004 USA |
| 代表者氏名 | Herriot Tabuteau Herriot Tabuteau |
| 代表者役職名 | Chairman of the Board Chief Executive Officer 取締役会長兼最高経営責任者 |
| 電話番号 | +1 212-203-5072 |
| 設立年月日 | 40909 |
| 市場名 | NASDAQ National Market System |
| ipoyear | 2015年 |
| 従業員数 | 25人 |
| url | www.axsome.com |
| nasdaq_url | https://www.nasdaq.com/symbol/axsm |
| adr_tso | ― |
| EBITDA | EBITDA（百万ドル） -27.84864 |
| 終値（lastsale） | 3.39 |
| 時価総額（marketcap） | 88997202.18 |
| 時価総額 | 時価総額（百万ドル） 93.50153 |
| 売上高 | 売上高（百万ドル） 0.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 81.62078 |
| 当期純利益 | 当期純利益（百万ドル） -26.95052 |
| 決算概要 | 決算概要 BRIEF: For the six months ended 30 June 2018 Axsome Therapeutics Inc revenues was not reported. Net loss decreased 13% to $13.1M. Lower net loss reflects Research and development - Other decrease of 6% to $10.1M (expense) Stock-based Compensation in SGA decrease of 9% to $788K (expense) Stock-based Compensation in R&D decrease of 21% to $221K (expense). Basic Earnings per Share excluding Extraordinary Items increased from -$0.71 to -$0.51. |
AXSMのテクニカル分析
AXSMのニュース
Immunomedics, Scientific Games: 5 Top Gainers for Monday 2020/09/14 20:21:52 The Street
Immunomedics, Scientific Games, Axsome Therapeutics, Seattle Genetics and Vaxart are some of the top gainers for Monday.
Earnings Scheduled For August 10, 2020 2020/08/10 08:10:24 Benzinga
Companies Reporting Before The Bell • Acacia Research Inc. (NASDAQ: ACTG ) is expected to report quarterly loss at $0.02 per share on revenue of $200.00 thousand. • Akebia Therapeutics Inc. (NASDAQ: AKBA ) is expected to report quarterly loss at $0.50 per share on revenue of $74.18 million. • Apyx Medical Inc. (NASDAQ: APYX ) is estimated to report quarterly loss at $0.21 per share on revenue of $1.96 million. • Avadel Pharmaceuticals Inc. (NASDAQ: AVDL ) is estimated to report quarterly loss at $0.10 per share on revenue of $7.37 million. • Axsome Therapeutics Inc. (NASDAQ: AXSM ) is estimated to report earnings for its second quarter. • Liberty Braves Group Inc. (NASDAQ: BATRK ) is estimated to report earnings for its second quarter. • Biohaven Pharmaceutical Inc. (NYSE: BHVN ) is expected to report earnings for its second quarter. • Black Knight Inc. (NYSE: BKI ) is expected to report quarterly earnings at $0.47 per share on revenue of $290.66 million. • Bluerock Residential Growth REIT, Inc.
Why Axsome Therapeutics Stock Is Sinking Today | The Motley Fool 2020/06/29 16:45:00 The Motley Fool
Some traders appear to be taking profits off the table after the stock's jump last week.
Thinking about trading options or stock in Axsome Therapeutics, Virgin Galactic, Dynavax Technologies, Big Lots, or Walt Disney? 2020/06/26 13:31:00 PR Newswire
NEW YORK, June 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AXSM, SPCE, DVAX, BIG, and DIS. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different…
Why Is Axsome (AXSM) Down 15.7% Since Last Earnings Report? 2020/06/07 15:30:16 Zacks Investment Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Earnings Scheduled For August 10, 2020 2020/08/10 08:10:24 Benzinga
Companies Reporting Before The Bell • Acacia Research Inc. (NASDAQ: ACTG ) is expected to report quarterly loss at $0.02 per share on revenue of $200.00 thousand. • Akebia Therapeutics Inc. (NASDAQ: AKBA ) is expected to report quarterly loss at $0.50 per share on revenue of $74.18 million. • Apyx Medical Inc. (NASDAQ: APYX ) is estimated to report quarterly loss at $0.21 per share on revenue of $1.96 million. • Avadel Pharmaceuticals Inc. (NASDAQ: AVDL ) is estimated to report quarterly loss at $0.10 per share on revenue of $7.37 million. • Axsome Therapeutics Inc. (NASDAQ: AXSM ) is estimated to report earnings for its second quarter. • Liberty Braves Group Inc. (NASDAQ: BATRK ) is estimated to report earnings for its second quarter. • Biohaven Pharmaceutical Inc. (NYSE: BHVN ) is expected to report earnings for its second quarter. • Black Knight Inc. (NYSE: BKI ) is expected to report quarterly earnings at $0.47 per share on revenue of $290.66 million. • Bluerock Residential Growth REIT, Inc.
Why Axsome Therapeutics Stock Is Sinking Today | The Motley Fool 2020/06/29 16:45:00 The Motley Fool
Some traders appear to be taking profits off the table after the stock's jump last week.
Thinking about trading options or stock in Axsome Therapeutics, Virgin Galactic, Dynavax Technologies, Big Lots, or Walt Disney? 2020/06/26 13:31:00 PR Newswire
NEW YORK, June 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AXSM, SPCE, DVAX, BIG, and DIS. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different…
Why Is Axsome (AXSM) Down 15.7% Since Last Earnings Report? 2020/06/07 15:30:16 Zacks Investment Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Axsome's (AXSM) Earnings Miss in Q1, Pipeline Progresses 2020/05/11 15:56:00 Zacks Investment Research
Axsome (AXSM) incurs a wider loss in the first quarter of 2020. However, the company is advancing well with the NDA for AXS-05 and AXS-07.
Why Axsome Therapeutics Stock Is Sinking Today | The Motley Fool 2020/06/29 16:45:00 The Motley Fool
Some traders appear to be taking profits off the table after the stock's jump last week.
Thinking about trading options or stock in Axsome Therapeutics, Virgin Galactic, Dynavax Technologies, Big Lots, or Walt Disney? 2020/06/26 13:31:00 PR Newswire
NEW YORK, June 26, 2020 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for AXSM, SPCE, DVAX, BIG, and DIS. Click a link below then choose between in-depth options trade idea report or a stock score report. Options Report – Ideal trade ideas on up to seven different…
Why Is Axsome (AXSM) Down 15.7% Since Last Earnings Report? 2020/06/07 15:30:16 Zacks Investment Research
Axsome (AXSM) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Axsome's (AXSM) Earnings Miss in Q1, Pipeline Progresses 2020/05/11 15:56:00 Zacks Investment Research
Axsome (AXSM) incurs a wider loss in the first quarter of 2020. However, the company is advancing well with the NDA for AXS-05 and AXS-07.
Why Axsome Is Touching The $100 Level For The First Time In Months 2020/04/27 14:33:43 Benzinga
Axsome Therapeutics Inc (NASDAQ: AXSM ), which was a high-flier for most of 2019, has come off the all-time highs reached late last year thanks to the COVID-19 pandemic and a negative readout in late March. Positive Phase 2/3 data released by the company Monday morning seems to have reignited the rally. Axsome said AXS-05, its investigational NMDA receptor antagonist, met the primary endpoint in a Phase 2/3 trial dubbed ADVANCE-1 that evaluated the candidate in Alzheimer's disease patients. AXS-05 rapidly, substantially and significantly … Full story available on Benzinga.com